Drug Search Results
More Filters [+]

PTT-4256

Alternative Names: PTT-4256, PTT 4256, PTT4256
Latest Update: None
Latest Update Note: None

Product Description

An internally discovered, oral, highly potent, and selective small molecule inhibitor of GPR65 that has demonstrated excellent drug-like properties and impressive monotherapy anti-tumour activity in preclinical models. (Sourced from: https://pathiostherapeutics.com/pathios-therapeutics-unveils-ptt-4256-a-highly-potent-and-selective-inhibitor-of-gpr65-in-presentation-at-american-association-for-cancer-research-aacr-annual-meeting-2023/)

Mechanisms of Action: GPR65 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PTT-4256

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title